Healthcare
Ono Pharmaceutical Co., Ltd.(OPHLF)
Live Price
Offline$14.55
+0.00% today
1Y Change
+44.69%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $1.09T
- Revenue Growth
- -3.1%
- EPS Growth
- -60.0%
- Dividend Yield
- 3.5%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ono Pharmaceutical Co., Ltd. (OPHLF) is a Healthcare stock with a market cap of $1.09T and listed on OTC. The stock last traded around $14.55 and up 44.7% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -3.1%, EPS growth of -60.0%, a dividend yield of 3.5%. What stands out right now is revenue -3.1%, EPS -60.0%, free cash flow -17.1% with operating margin 16.3% and ROIC 7.0%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 17.4 and price/sales 2.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines OPHLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.1% vs +7.6% peer median
Operating Margin
Below sector median
+16.3% vs +19.4% peer median
P/E
Below sector median
17.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -3.1% and EPS is at -60.0%, with operating margin around 16.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 2, 2026 | +38.5% | +0.0% | +0.0% | +9.7% |
2025 Oct 30, 2025 | +16.4% | +0.0% | +0.0% | +8.9% |
Benchmark Edge
OPHLF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OPHLF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OPHLF Max Drawdown
-27.69%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OPHLF and SPY.
Company Overview
Ono Pharmaceutical Co., Ltd.
Other OTC
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
- Leadership
- Gyo Sagara
- IPO Date
- Mar 21, 2013
- Employees
- 3.9k
- Street Address
- 8-2, Kyutaromachi 1-chome
- Mailing
- Osaka, 541-8564
- Region
- Osaka, JP
- Reporting Currency
- USD
- Investor Line
- 81 6 6263 5670
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 17.4
- EV/EBITDA
- 8.5
- Price/Sales
- 2.1
- Price/Book
- 1.3
Growth
- Revenue
- -3.1%
- EPS
- -60.0%
- Free Cash Flow
- -17.1%
Profitability
- Gross Margin
- 69.8%
- Operating Margin
- 16.3%
- Net Margin
- 12.3%
- ROE
- 7.8%
- ROIC
- 7.0%
Balance Sheet
- Debt/Equity
- 0.15
- Current Ratio
- 3.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.